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Abstract: Conotoxins are a pool of disulfide-rich peptide neurotoxins produced by cone snails for
predation and defense. They are a rich reservoir of novel ligands for ion channels, neurotransmitter
receptors and transporters in the nervous system. In this study, we identified a novel conotoxin
component, O-conotoxin GeXXVIIA, from the venom of Conus generalis. The native form of this
component is a disulfide-linked homodimer of a 5-Cys-containing peptide. Surprisingly, our
electrophysiological studies showed that, in comparison to the folded monomers, the linear peptide
of this toxin had the highest inhibitory activity at the human α9α10 nicotinic acetylcholine receptor
(nAChR), with an IC50 of 16.2 ± 1.4 nM. The activities of the N-terminal and C-terminal halves
of the linear toxin are markedly reduced compared with the full-length toxin, suggesting that the
intact sequence is required to potently inhibit the hα9α10 nAChR. α9α10 nAChRs are expressed not
only in the nervous system, but also in a variety of non-neuronal cells, such as cochlear hair cells,
keratinocytes, epithelial and immune cells. A potent inhibitor of human α9α10 nAChRs, such as
GeXXVIIA, would facilitate unraveling the functions of this nAChR subtype. Furthermore, this
unusual nAChR inhibitor may lead to the development of novel α9α10 nAChR-targeting drugs.
Keywords: conotoxin; O-superfamily; nicotinic receptor; α9α10; linear peptide

1. Introduction
The predatory cone snails (genus Conus) use their venoms as a weapon for predation and
defense [1]. Based on their prey, cone snails are classified into fish-, mollusk-, or worm-hunting species,
implying that their predation venoms may be largely different. Under the defensive evolutionary
pressure, all cone snails have also developed defensive venoms against predators [2,3]. No matter what
the purpose is, their venoms are primarily composed of an array of disulfide-rich peptides (conotoxins)
that target membrane ion channels and neurotransmitter receptors in the nervous system [4]. As the
number of conotoxin components is estimated to be in excess of 200,000, they are considered as a
reservoir for novel drug leads for neuroscience research and disease treatment [5–7]. For example,
ω-conotoxin MVIIA isolated from C. magus acts as a selective N-type Ca2+ channel inhibitor and has
been developed as an analgesic drug commercially known as Ziconotide or Prialt [8–10].
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Conotoxins are produced initially as gene-encoded polypeptide precursors and then maturated
through proteolytic cleavages, and often post-translational modifications. Based on the signal
peptide sequences of conotoxin precursors, the highly variable conotoxins are grouped into different
superfamilies [11]. However, conotoxins belonging to the same superfamily do not necessarily have
the same cysteine framework or functional target. One remarkable example is the O-superfamily
conotoxins that include Ca2+ channel-inhibiting ω-conotoxins, K+ channel-inhibiting κ-conotoxins,
Na+ channel-modifying δ-conotoxins, and Na+ channel-inhibiting µO-conotoxins [12].
Nicotinic acetylcholine receptors (nAChRs) are key in transmitting signals in the central and
peripheral nervous systems, opening a cation-selective pore upon the binding of acetylcholine (ACh) to
the extracellular domain [13]. nAChRs exist as homo- or hetero-pentameric channels and 17 subunits
have been recognized in vertebrate species (α1–α10, β1–β4, γ, δ, and ε). The skeletal muscle nAChR
subtype is composed of α1, β1, δ, and ε (adult isoform) or γ (fetal isoform) subunits at 2:1:1:1 ratio.
In contrast, neuronal nAChR subtypes are composed of only α and β subunits except for α7, α9, and
α10 subunits, which can form functional receptors without the participation of β subunits. Each nAChR
subtype has distinct tissue expression, pharmacological properties and physiological functions [14].
Although the heteromeric α9α10 nAChR is generally characterized as neuronal, it is also expressed
in non-neuronal cells such as cochlear hair cells, keratinocytes, pituitary pars tuberalis, epithelial and
immune cells [15,16]. Investigation of the physiological roles of the α9α10 subtype would be greatly
facilitated by potent inhibitors of the human (h) α9α10 nAChR. In this study, we identified a novel
5 Cys-containing conotoxin from the venom of Conus generalis. The precursor sequence of this toxin
demonstrated that it is a member of the O1-superfamily. Although the native form of this toxin is a
disulfide-linked homodimer, surprisingly the linear peptide of this toxin is a potent inhibitor of hα9α10
nAChR, with an IC50 of 16.2 ± 1.4 nM. This novel nAChR inhibitor may lead to the development of
novel α9α10 nAChR-targeting drugs.
2. Results
2.1. Purification and Identification of a Five-Cys-Containing Component from the Venom of Conus generalis
The separation of the C. generalis crude venom on a C18 semi-preparative reverse-phase HPLC
column gave a series of peaks (Figure 1a). One minor peak, apart from two major peaks that have
been studied previously [17,18], was focused in this study. A secondary separation using a C18
analytical column (Figure 1b) revealed that there are three components in this minor peak, with
the second having a molecular mass of 9695 Da. Interestingly, reduction of this component with
dithiothreitol (DTT) changed its molecular mass to 4853 Da (Figure 1c), indicating that this component
is also a disulfide-linked homodimer, similar to αD-GeXXA [18]. Subsequently, alkylation with
N-ethylmaleimide (NEM) of the reduced monomeric peptide increased the molecular mass to 5479 Da,
which confirmed the presence of five Cys residues in this polypeptide chain (Figure 1d). The odd
number of Cys residues is unique for conotoxins, which prompted us to investigate further.
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Figure 1. Purification and identification of O‐conotoxin GeXXVIIA from Conus generalis. (a)
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Figure 2. cDNA sequence of O‐GeXXVIIA. (a) The cDNA sequence of GeXXVIIA and the
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Figure 5. Antagonist potencies of GeXXVIIA-L and GeXXVIIA-L-Nter at the rodent α1β1εδ and
human α9α10 nAChRs. (a) Inhibition of ACh‐evoked peak current amplitude mediated by rα1β1εδ
human α9α10 nAChRs. (a) Inhibition of ACh-evoked peak current amplitude mediated by rα1β1εδ
and hα9α10 nAChRs by GeXXVIIA‐m1, GeXXVIIA‐L, GeXXVIIA‐L‐Nter, and GeXXVIIA‐L‐Cter at 5
and hα9α10 nAChRs by GeXXVIIA-m1, GeXXVIIA-L, GeXXVIIA-L-Nter, and GeXXVIIA-L-Cter at
μM (n = 1 oocyte) and 300 nM (n = 3–7 oocytes) peptide concentrations. Error bars indicate SEM. (b)
5 µM (n = 1 oocyte) and 300 nM (n = 3–7 oocytes) peptide concentrations. Error bars indicate SEM.
Concentration‐response curves obtained for GeXXVIIA‐L and GeXXVIIA‐L‐Nter inhibition of
(b) Concentration-response curves obtained for GeXXVIIA-L and GeXXVIIA-L-Nter inhibition of
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membrane potentials tested (45.6 ± 7.3% at −120 mV (n = 5), 44.9 ± 5.6% at −80 mV (n = 9), and 45.6 ±
Furthermore, GeXXVIIA-L (16.2 nM) inhibition of ACh-evoked currents at hα9α10 nAChR was similar
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at all membrane potentials tested (45.6 ± 7.3% at −120 mV (n = 5), 44.9 ± 5.6% at −80 mV (n = 9), and
45.6 ± 8.1% at −40 mV (n = 4)). These results indicate that GeXXVIIA-L inhibition of hα9α10 nAChR
is voltage-independent, suggesting that the peptide does not enter the membrane electric field and is
unlikely to be an open channel pore blocker.
3. Discussion
Conotoxins are well known for their structural and functional diversity. In this study, we identified
a novel conotoxin GeXXVIIA from the South China Sea mollusk C. generalis and classified it as a member
of the O1-superfamily conotoxins. However, the mature peptide sequence of GeXXVIIA contains
five Cys residues, which is distinct from the cysteine framework VI/VII (C–C–CC–C–C) in most of
the O-superfamily conotoxins [12]. Comparison with the cDNA sequence of Mik41 suggests that the
cysteine framework of GeXXVIIA may well be the result of a point mutation that changes the codon
of the fourth Cys (TGC) in Mik41 into a codon of Arg (CGC) in GeXXVIIA [19]. The random point
mutation in conotoxin genes has been found to be one of the mechanisms for conotoxin diversity [21].
Due to this unique cysteine framework, we propose that GeXXVIIA represents a new branch of
the O1-superfamily.
It is uncommon for conotoxins to have odd number of Cys residues, as conotoxins are often
disulfide-linked monomers, whereas an uneven number of Cys residues suggests the existence of
interchain disulfide bond. Other conotoxins containing an odd number of Cys residues include TxXIIIA
(with five Cys residues in the short sequence TSDCCFYNCCC) and the con-ikot-ikot (with 13 Cys
residues in the mature sequence) [22,23]. Both of them form disulfide-linked homodimers, as believed
for the native GeXXVIIA. However, the elucidation of the dimerization linkage remains a challenge.
So far, the linkage is known only for two dimeric conotoxins, con-ikot-ikot and αD-GeXXA, by X-ray
structure determination in both cases [18,24]. However, the very low abundance of the natural dimeric
GeXXVIIA is a major obstacle for the structural study of this toxin.
Following the report of GeXIVA [20], we discovered that the monomeric GeXXVIIA has
nAChR-inhibitory activity. Furthermore, different disulfide linkages were found not to change much
the nAChR-inhibitory activity of GeXXVIIA (Figure 3), which is consistent with the properties of
GeXIVA [20]. As the predicted sequence of GeXIVA differs from GeXXVIIA sequence mainly by the
lack of N-terminal 13 residues, it appears that the basal nAChR-inhibitory activity of GeXXVIIA is
mediated by the C-terminal part analogous to GeXIVA. However, quantitative comparison of the toxin
activities suggests that the existence of the N-terminal extension in GeXXVIIA enhances the potency
and specificity on hα9α10 nAChR.
The α9α10 subtype nAChRs were originally characterized in cochlear hair cells where they
function in mediating synaptic transmission between the olivocochlear system and auditory hair
cells of the cochlea [25–27]. Other studies reported that α9α10 nAChRs are expressed in different
tissues, including dorsal root ganglia, skin, lymphocyte, sperm, and immune cells [28–32]. Potent
α9α10-specific antagonizing conotoxins, such as α-RgIA, α-Vc1.1 and the bead isomer of GeXIVA, have
been shown to provide long lasting relief in rat models of neuropathic pain, although the underlying
mechanism remains controversial [20,33–39]. Recent studies have also shown that the α9 subunit is
over-expressed in breast tumors [40]. Therefore, considering the physiological importance of hα9α10
nAChR, ligands with high potency on this nAChR subtype would be of great potential. However,
the development of hα9α10 nAChR-selective conotoxins is hindered by the fact that most of the
α9α10 subtype-specific conotoxins have only been studied on the rat nAChR subtype, examples
including α-RgIA, α-Vc1.1, αS-GVIIIA, and αO-GeXIVA (Table 1). Prior to this study, only αD-GeXXA
(IC50 = 28 nM) [18] and GeXIVA bead isomer (IC50 = 20 nM) [41] showed high potency at the hα9α10
subtype. The novel conotoxin GeXXVIIA identified in this study has a similarly high potency at
the hα9α10 subtype (IC50 = 16.2 nM). However, unlike the conotoxins discussed above, in which
their potency is dependent on the disulfide folding, GeXXVIIA is a more potent inhibitor as a
linear peptide. This unique property not only facilitates the synthesis and use of this toxin, but
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also suggests that GeXXVIIA has an unusual nAChR-inhibition mechanism. Indeed, the comparable
inhibition by GeXXVIIA-L tested with different ACh concentrations or at different membrane potentials
demonstrates that GeXXVIIA-L is neither a competitive antagonist, nor a channel pore blocker of
nAChR. Most likely, GeXXVIIA-L is a new class of nAChR allosteric inhibitor.
It is unusual among conotoxins that the linear GeXXVIIA is more potent than its folded
counterparts (Figure 5a). This suggests that the interaction between GeXXVIIA and α9α10 nAChR is
improved with an extended peptide of GeXXVIIA, most likely because the nAChR-binding sites in
GeXXVIIA are distributed along the sequence of this toxin. This is probably why both the two halves
of GeXXVIIA have diminished nAChR-inhibitory activities compared to the full-length toxin. In other
words, both the two halves of linear GeXXVIIA cooperatively contribute to the high potency of this
toxin. Given the unusual high content of basic residues (nine Arg and one Lys out of 41 residues) in the
GeXXVIIA sequence (Figure 2), it is highly likely that the electrostatic interaction with the nAChR acidic
residues plays a major role in binding. Consistent with this proposal, a strongly electronegative surface
was identified in the extracellular vestibule from the crystal structural study of α4β2 nAChR [42].
Identification of the binding site of GeXXVIIA on α9α10 nAChR may furnish valuable information in
understanding the gating mechanism of this receptor.
In summary, we have identified a novel O-superfamily conotoxin GeXXVIIA from the venom
of C. generalis. We discovered that the linear peptide of GeXXVIIA can strongly inhibit the activity
of the human α9α10 nAChR with an IC50 of 16.2 nM. Although nAChR may not be the target of the
native GeXXVIIA toxin that is a disulfide-linked homodimer, the high potency of its linear peptide on
hα9α10 nAChR per se is of great interest. These findings suggest an unusual inhibition mechanism
on nAChR, which merits further investigation, both for the understanding of nAChR structure and
function and for the development of novel nAChR inhibitors.
Table 1. Conotoxins with high potency on α9α10 nAChRs.
SuperFamily

Toxin
Name

Toxin Sequence

Species of
α9α10 nAChR

IC50 (nM)

Reference

O

GeXXVIIA

C. generalis

ALMSTGTNYRLLKTCRGSGRYCRSPYD
CRRRYCRRISDACV

H. sapiens

16.2

This study

O

GeXIVA

C. generalis

TCRSSGRYCRSPYDRRRRYCRRITDACV

R. norvegicus
H. sapiens

4.6
20.3

[20]
[41]

A

RgIA

C. regius

GCCSDPRCRYRCR

R. norvegicus
H. sapiens

1.5
494

[43]

A

Vc1.1

C. victoriae

GCCSDPRCNYDHPEIC *

R. norvegicus

19

[33]

R. norvegicus

9.8

[44]

R. norvegicus
H. sapiens

1.2
28

[12]

Conus Species

S

GVIIIB

C. geographus

SGSTCTCFTSTNCQGSCECLSPPGCYCS
NNGIRQRGCSCTCPGT *

D

GeXXA

C. generalis

DVHRP CQSVRPGRVWGKCCLTRLCST
MCCARADCTCVYHTWRGHGCSCVM

* C-terminal amidation.

4. Materials and Methods
4.1. Toxin Isolation and Purification
Specimens of C. generalis were collected from the South China Sea, near the coast of Sanya,
Hainan Island, China. In order to extract the crude venom, the venom ducts were homogenized and
suspended in 0.1% (v/v) trifuoroacetic acid (TFA). After centrifugation at 12,000× g at 4 ◦ C for 15 min,
the supernatant was collected and the pellet was stirred in 0.1% TFA for 30 min, then re-centrifuged.
Precipitates were pooled and re-extracted successively with 0.1% TFA in 20, 30, 40 and 50% acetonitrile.
Supernatants were combined, lyophilized, and stored at −20 ◦ C.
To purify the conotoxins, the lyophilized crude venom was dissolved in Buffer A (0.1% TFA).
After centrifugation, the supernatant was applied on a ZORBAX C18 semi-preparative column
(9.4 × 250 mm, Agilent, Santa Clara, CA, USA) and eluted with a gradient of buffer B (0.1% TFA
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in 100% acetonitrile) using an Agilent 1100 HPLC system. Further purification was performed on a
ZORBAX C18 analytical column (4.6 × 250 mm, Agilent, Santa Clara, CA, USA).
4.2. Toxin Characterization and N-Terminal Sequencing
The purified conotoxin component was dissolved in the reduction buffer of 100 mM Tris-HCl,
pH 8.7 and 2 mM EDTA, and reduced with a 100-fold excess of dithiothreitol (DTT) at 37 ◦ C for 1 h.
The reduced peptide was purified on a ZORBAX C18 analytical column (4.6 × 250 mm, Agilent, Santa
Clara, CA, USA). Thiol groups were alkylated with 10 mM N-ethylmaleimide (NEM) in the reduction
buffer at 37 ◦ C in the dark for 0.5 h. The modified peptide was purified by a C18 reverse-phase column
on HPLC, and directly used for N-terminal sequencing on ABI 491A Procise® Protein Sequencing
System (Applied Biosystems, Foster City, CA, USA).
The mass spectrometry analyses of the native, reduced and S-alkylated toxins were performed
on a Q-trap mass spectrometer (Applied Biosystems, Foster City, CA, USA), using the scan type of
Enhanced MS. The apparatus was equipped with a TurboIonSpray source and operated in positive
ionization mode.
4.3. cDNA Cloning
Total RNA was extracted from homogenized venom duct tissues using Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol. Reverse transcription was carried out
using a universal oligo dT-containing adapter primer 5’-GGC CAC GCG TCG ACT AGT AC (dT)17 -3’
(Superscript II Kit, Invitrogen, Carlsbad, CA, USA). The resulting cDNA was used as a template for
cDNA-cloning PCR.
Complete cDNA sequence of this toxin was obtained by overlapping the 3’- and 5’-partial cDNA
sequences. The 3’-partial cDNA was first amplified through two rounds of PCR. The first PCR
reaction was carried out using a degenerate oligonucleotide primer GSP1 (5’-GCNYTRATGTCN
ACNGGNACNAAYTAY-3’, Y: T/C, R: G/A, N: A/T/G/C), designed based on the N-terminal
sequence (ALMSTGTNY-) and an outer primer provided by the 3’-RACE kit (Takara, Dalian, China).
The second round of PCR amplification was carried out using the product of the first round PCR as
the template by pairing the upstream primer GSP2 (5’-ATGTCNACNGGNACNAAYTAY-3’), designed
based on the partial N-terminal sequence (-MSTGTNY-) with an inner primer provided by the kit.
The ~250 bp PCR products were ligated into pGEM-T Easy vector (Promega, Madison, WI, USA)
for sequencing.
Sequence comparison of the 3’-partial cDNA obtained above with other conotoxins showed that
the mature peptide sequence of this toxin displays a high degree of homology to that of O-superfamily
conotoxin Mik41 [19]. As the signal peptide of the O-superfamily is highly conserved, an upstream
primer SP1 (5’-CATCGTCAAGATGAAACTGACG-3’) was designed based on the known cDNA
sequence of Mik41. According to the 3’-partial sequence of GeXXVIIA, we designed a specific antisense
primer GSP3 (5’-CACAGGTATGGATGACTCAGG’-3’) corresponding to the 3’-untranslated region.
The 5’-partial cDNA of GeXXVIIA was amplified from the total cDNAs of C. generalis with these two
primers and ligated into pGEM-T Easy vector (Promega, Madison, WI, USA) for sequencing.
4.4. Peptide Synthesis and Refolding
The linear peptide of GeXXVIIA, with all 5 Cys residues unprotected, was synthesized by the
Chinese Peptide Company (Hangzhou, China). Oxidative folding of the purified linear peptide (20 µM)
was performed at 4 ◦ C for one week in a buffer comprising 50 mM Tris-HCl, pH 8.0, 400 mM arginine,
0.02 mM DTT, and 0.3 mM oxidized DTT. The oxidized products were purified on a ZORBAX C18
HPLC analytical column (4.6 × 250 mm, Agilent) with isocratic elution. Each monomer component
was applied to a secondary HPLC purification.
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4.5. Peptide Alkylation and Digestion by Protease Asp-N
The synthesized linear GeXXVIIA was alkylated with 10 mM iodoacetamide (IAA) in 100 mM
Tris-HCl, pH 8.7, and 2 mM EDTA at 22 ◦ C in the dark for 1 h. The alkylated linear peptide GeXXVIIA-L
was purified on a ZORBAX C18 HPLC analytical column (4.6 × 250 mm, Agilent). The digestion of
alkylated GeXXVIIA-L was carried out in 100 mM Tris-HCl, pH 8.5, using 3 µg/mL Asp-N (Sigma,
St Louis, MO, USA) at 37 ◦ C for 18 h. The digested products were separated on a ZORBAX C18 HPLC
analytical column (4.6 × 250 mm, Agilent).
4.6. Oocyte Two-Electrode-Voltage Clamp Recordings
Oocyte preparation, RNA preparation, and expression of nAChR subunits in Xenopus oocytes
were performed as described previously [12]. All procedures were approved by the University of
Sydney Animal Ethics Committee. Plasmid constructs of rat (α1, β1, and δ), mouse (ε) and human
(α3, α4, α7, α9, α10, β2, and β4) nAChR subunits were linearized for in vitro mRNA synthesis using
mMessage mMachine transcription kit (AMBION, Forster City, CA, USA).
Stage V–VI Xenopus laevis oocytes were defolliculated with collagenase (Worthington Biochemical
Corp., Lakewood, NJ, USA) at room temperature (20–25 ◦ C) for 1 h in OR-2 solution containing (in mM)
82.5 NaCl, 2 KCl, 1 MgCl2 , and 5 HEPES at pH 7.4. Oocytes were injected with 5 ng cRNA for hα3β2,
α3β4, α4β2, α4β4, α7 or rodent α1β1δε nAChRs, and 35 ng cRNA for hα9α10 nAChR (concentration
confirmed spectrophotometrically and by gel electrophoresis) using glass pipettes. Oocytes were
incubated at 18 ◦ C in sterile ND96 solution composed of (in mM) 96 NaCl, 2 KCl, 1 CaCl2 , 1 MgCl2 ,
and 5 HEPES at pH 7.4, supplemented with 5% fetal bovine serum, 50 mg/L gentamicin (GIBCO,
Grand Island, NY, USA) and 10,000 U/mL penicillin-streptomycin (GIBCO, Grand Island, NY, USA).
Membrane currents were recorded from oocytes expressing nAChRs at room temperature, using
a GeneClamp 500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale, CA,
USA) in a two-electrode voltage-clamp recording configuration (holding potential −80 mV). In a series
of experiments, the effect of different membrane potentials (−120, −80, and −40 mV) on GeXXVIIA
inhibition of hα9α10 nAChRs was tested. Voltage-recording and current-injecting microelectrodes
were pulled from GC150T-7.5 borosilicate glass (Harvard Apparatus Ltd., Holliston, MA, USA), giving
tip resistances of 0.3–1.5 MΩ when filled with 3 M KCl. Oocytes were perfused with ND96 solution at
a rate of 2 mL/min. Oocytes expressing hα9α10 nAChRs were incubated in 100 µM BAPTA-AM ~3 h
before recording and perfused with ND115 solution containing (in mM): 115 NaCl, 2.5 KCl, 1.8 CaCl2 ,
and 10 HEPES at pH 7.4.
Initially, oocytes were briefly washed with bath solution (ND96/ND115) followed by three
applications of acetylcholine (ACh) at half-maximal effective concentration (EC50 ) of 6 µM for hα3β2,
hα9α10 and hα4β4 nAChRs, 300 µM for hα3β4, 100 µM for hα7, 3 µM for hα4β2, and 1 µM for
rα1β1εδ nAChRs. Washout with bath solution was done for 3 min between ACh applications.
GeXXVIIA-L inhibition of hα9α10 nAChRs was also examined at different ACh concentrations as
indicated. Oocytes were incubated with peptides for 5 min with the perfusion system turned off,
followed by co-application of ACh and peptide with flowing bath solution. All peptide solutions were
prepared in ND96/ND115 + 0.1% bovine serum albumin. Peak current amplitude evoked by ACh was
measured before and following incubation with peptide in order to determine the effect on specific
nAChR subtype. Concentration-dependent response curves for antagonists were fitted by unweighted
nonlinear regression to the following logistic equation:
Ex = Emax XnH /(XnH + IC50 nH ),

(1)

where Ex is the response, X is the antagonist concentration, Emax is the maximal response, nH is the slope
factor, and IC50 is the antagonist concentration giving half-maximal response. All electrophysiological
data were pooled (n = 4–11 oocytes for each data point) and represented as means ± standard error of
the mean (SEM). The IC50 was determined from the concentration-response curve and reported with
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error of the fit. Computation was performed using GraphPad Prism 5 (GraphPad Software, La Jolla,
CA, USA).
Acknowledgments: This work was supported by National Natural Science Foundation of China (grant nos.
31570771 and 31500626) and the Australian Research Council (ARC Discovery Grant DP150103990 to D.J.A.).
The cDNA of GeXXVIIA was deposited into Genbank with an accession number KY523472.
Author Contributions: C.W. and D.J.A. designed and supervised the experiments; S.J., S.X., and X.S. performed
the experiments of peptide characterization; H.-S.T. performed the experiments of electrophysiological activity;
and C.W. and D.J.A. wrote the paper with input from all the authors.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.

3.

4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.

19.

Olivera, B.M. Conus Venom Peptides: Reflections from the biology of clades and species. Annu. Rev. Ecol. Syst.
2002, 33, 25–47. [CrossRef]
Dutertre, S.; Jin, A.H.; Vetter, I.; Hamilton, B.; Sunagar, K.; Lavergne, V.; Dutertre, V.; Fry, B.G.; Antunes, A.;
Venter, D.J.; et al. Evolution of separate predation- and defence-evoked venoms in carnivorous cone snails.
Nat. Commun. 2014, 5, 3521. [CrossRef] [PubMed]
Olivera, B.M.; Showers Corneli, P.; Watkins, M.; Fedosov, A. Biodiversity of cone snails and other venomous
marine gastropods: Evolutionary success through neuropharmacology. Annu. Rev. Anim. Biosci. 2014, 2,
487–513. [CrossRef] [PubMed]
Terlau, H.; Olivera, B.M. Conus venoms: A rich source of novel ion channel-targeted peptides. Physiol. Rev.
2004, 84, 41–68. [CrossRef] [PubMed]
Lewis, R.J.; Dutertre, S.; Vetter, I.; Christie, M.J. Conus venom peptide pharmacology. Pharmacol. Rev. 2012,
64, 259–298. [CrossRef] [PubMed]
Essack, M.; Bajic, V.B.; Archer, J.A. Conotoxins that confer therapeutic possibilities. Mar. Drugs 2012, 10,
1244–1265. [CrossRef] [PubMed]
Mir, R.; Karim, S.; Kamal, M.A.; Wilson, C.M.; Mirza, Z. Conotoxins: Structure, therapeutic potential and
pharmacological applications. Curr. Pharm. Des. 2016, 22, 582–589. [CrossRef] [PubMed]
Wermeling, D.P. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the
treatment of chronic pain. Pharmacotherapy 2005, 25, 1084–1094. [CrossRef] [PubMed]
Schmidtko, A.; Lotsch, J.; Freynhagen, R.; Geisslinger, G. Ziconotide for treatment of severe chronic pain.
Lancet 2010, 375, 1569–1577. [CrossRef]
Webster, L.R. The relationship between the mechanisms of action and safety profiles of intrathecal morphine
and Ziconotide: A review of the literature. Pain Med. 2015, 16, 1265–1277. [CrossRef] [PubMed]
Kaas, Q.; Yu, R.; Jin, A.H.; Dutertre, S.; Craik, D.J. ConoServer: Updated content, knowledge, and discovery
tools in the conopeptide database. Nucleic Acids Res. 2012, 40, D325–D330. [CrossRef] [PubMed]
Heinemann, S.H.; Leipold, E. Conotoxins of the O-superfamily affecting voltage-gated sodium channels.
Cell. Mol. Life Sci. 2007, 64, 1329–1340. [CrossRef] [PubMed]
Gotti, C.; Clementi, F. Neuronal nicotinic receptors: From structure to pathology. Prog. Neurobiol. 2004, 74,
363–396. [CrossRef] [PubMed]
Albuquerque, E.X.; Pereira, E.F.; Alkondon, M.; Rogers, S.W. Mammalian nicotinic acetylcholine receptors:
From structure to function. Physiol. Rev. 2009, 89, 73–120. [CrossRef] [PubMed]
Del Bufalo, A.; Cesario, A.; Salinaro, G.; Fini, M.; Russo, P. α9α10 nicotinic acetylcholine receptors as target
for the treatment of chronic pain. Curr. Pharm. Des. 2014, 20, 6042–6047. [CrossRef] [PubMed]
Vázquez, A. α9α10 acetylcholine receptors: Structure and functions. Neurotransmitter 2016, 3, e1298.
Xu, S.; Shao, X.; Yan, M.; Chi, C.; Lu, A.; Wang, C. Identification of Two Novel O2-Conotoxins from
Conus generalis. Int. J. Pept. Res. Ther. 2015, 21, 81–89. [CrossRef]
Xu, S.; Zhang, T.; Kompella, S.N.; Yan, M.; Lu, A.; Wang, Y.; Shao, X.; Chi, C.; Adams, D.J.; Ding, J.; et al.
Conotoxin αD-GeXXA utilizes a novel strategy to antagonize nicotinic acetylcholine receptors. Sci. Rep.
2015, 5, 14261. [CrossRef] [PubMed]
Luo, S.; Zhangsun, D.; Feng, J.; Wu, Y.; Zhu, X.; Hu, Y. Diversity of the O-superfamily conotoxins from
Conus miles. J. Pept. Sci. 2007, 13, 44–53. [CrossRef] [PubMed]

Mar. Drugs 2017, 15, 170

20.

21.
22.

23.
24.
25.
26.

27.
28.

29.

30.

31.
32.

33.

34.

35.

36.
37.
38.

39.

12 of 13

Luo, S.; Zhangsun, D.; Harvey, P.J.; Kaas, Q.; Wu, Y.; Zhu, X.; Hu, Y.; Li, X.; Tsetlin, V.I.; Christensen, S.; et al.
Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine
receptor antagonist. Proc. Natl. Acad. Sci. USA 2015, 112, E4026–E4035. [CrossRef] [PubMed]
Lu, A.; Yang, L.; Xu, S.; Wang, C. Various conotoxin diversifications revealed by a venomic study of
Conus flavidus. Mol. Cell. Proteom. 2014, 13, 105–118. [CrossRef] [PubMed]
Walker, C.S.; Jensen, S.; Ellison, M.; Matta, J.A.; Lee, W.Y.; Imperial, J.S.; Duclos, N.; Brockie, P.J.;
Madsen, D.M.; Isaac, J.T.; et al. A novel Conus snail polypeptide causes excitotoxicity by blocking
desensitization of AMPA receptors. Curr. Biol. 2009, 19, 900–908. [CrossRef] [PubMed]
Quinton, L.; Gilles, N.; De Pauw, E. TxXIIIA, an atypical homodimeric conotoxin found in the Conus textile
venom. J. Proteom. 2009, 72, 219–226. [CrossRef] [PubMed]
Chen, L.; Durr, K.L.; Gouaux, E. X-ray structures of AMPA receptor-cone snail toxin complexes illuminate
activation mechanism. Science 2014, 345, 1021–1026. [CrossRef] [PubMed]
Elgoyhen, A.B.; Johnson, D.S.; Boulter, J.; Vetter, D.E.; Heinemann, S. α9: An acetylcholine receptor with
novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994, 79, 705–715. [CrossRef]
Elgoyhen, A.B.; Vetter, D.E.; Katz, E.; Rothlin, C.V.; Heinemann, S.F.; Boulter, J. α10: A determinant of
nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells.
Proc. Natl. Acad. Sci. USA 2001, 98, 3501–3506. [CrossRef] [PubMed]
Elgoyhen, A.B.; Katz, E.; Fuchs, P.A. The nicotinic receptor of cochlear hair cells: A possible
pharmacotherapeutic target? Biochem. Pharmacol. 2009, 78, 712–719. [CrossRef] [PubMed]
Haberberger, R.V.; Bernardini, N.; Kress, M.; Hartmann, P.; Lips, K.S.; Kummer, W. Nicotinic acetylcholine
receptor subtypes in nociceptive dorsal root ganglion neurons of the adult rat. Auton. Neurosci. 2004, 113,
32–42. [CrossRef] [PubMed]
Kurzen, H.; Berger, H.; Jager, C.; Hartschuh, W.; Naher, H.; Gratchev, A.; Goerdt, S.; Deichmann, M.
Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. J. Investig. Dermatol.
2004, 123, 937–949. [CrossRef] [PubMed]
Peng, H.; Ferris, R.L.; Matthews, T.; Hiel, H.; Lopez-Albaitero, A.; Lustig, L.R. Characterization of the human
nicotinic acetylcholine receptor subunit α9 (CHRNA9) and α10 (CHRNA10) in lymphocytes. Life Sci. 2004,
76, 263–280. [CrossRef] [PubMed]
Kumar, P.; Meizel, S. Nicotinic acetylcholine receptor subunits and associated proteins in human sperm.
J. Biol. Chem. 2005, 280, 25928–25935. [CrossRef] [PubMed]
Simard, A.R.; Gan, Y.; St-Pierre, S.; Kousari, A.; Patel, V.; Whiteaker, P.; Morley, B.J.; Lukas, R.J.; Shi, F.D.
Differential modulation of EAE by α9*- and β2*-nicotinic acetylcholine receptors. Immunol. Cell Biol. 2013,
91, 195–200. [CrossRef] [PubMed]
Vincler, M.; Wittenauer, S.; Parker, R.; Ellison, M.; Olivera, B.M.; McIntosh, J.M. Molecular mechanism for
analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors. Proc. Natl. Acad. Sci. USA
2006, 103, 17880–17884. [CrossRef] [PubMed]
Callaghan, B.; Haythornthwaite, A.; Berecki, G.; Clark, R.J.; Craik, D.J.; Adams, D.J. Analgesic α-conotoxins
Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation.
J. Neurosci. 2008, 28, 10943–10951. [CrossRef] [PubMed]
Mohammadi, S.A.; Christie, M.J. Conotoxin interactions with α9α10-nAChRs: Is the α9α10-nicotinic
acetylcholine receptor an important therapeutic target for pain management? Toxins (Basel) 2015, 7, 3916–3932.
[CrossRef] [PubMed]
Vincler, M.; McIntosh, J.M. Targeting the α9α10 nicotinic acetylcholine receptor to treat severe pain.
Expert Opin. Ther. Targets 2007, 11, 891–897. [CrossRef] [PubMed]
McIntosh, J.M.; Absalom, N.; Chebib, M.; Elgoyhen, A.B.; Vincler, M. α9 nicotinic acetylcholine receptors
and the treatment of pain. Biochem. Pharmacol. 2009, 78, 693–702. [CrossRef] [PubMed]
Pacini, A.; Micheli, L.; Maresca, M.; Branca, J.J.; McIntosh, J.M.; Ghelardini, C.; Di Cesare Mannelli, L.
The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin
treatment. Exp. Neurol. 2016, 282, 37–48. [CrossRef] [PubMed]
Adams, D.J.; Callaghan, B.; Berecki, G. Analgesic conotoxins: Block and G protein-coupled receptor
modulation of N-type CaV 2.2 calcium channels. Br. J. Pharmacol. 2012, 166, 486–500. [CrossRef] [PubMed]

Mar. Drugs 2017, 15, 170

40.

41.

42.
43.
44.

13 of 13

Lee, C.H.; Huang, C.S.; Chen, C.S.; Tu, S.H.; Wang, Y.J.; Chang, Y.J.; Tam, K.W.; Wei, P.L.; Cheng, T.C.;
Chu, J.S.; et al. Overexpression and activation of the α9-nicotinic receptor during tumorigenesis in human
breast epithelial cells. J. Natl. Cancer Inst. 2010, 102, 1322–1335. [CrossRef] [PubMed]
Zhangsun, D.; Zhu, X.; Kaas, Q.; Wu, Y.; Craik, D.J.; McIntosh, J.M.; Luo, S. αO-Conotoxin GeXIVA disulfide
bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency
and selectivity for the human α9α10 subtype. Neuropharmacology 2017. [CrossRef] [PubMed]
Morales-Perez, C.L.; Noviello, C.M.; Hibbs, R.E. X-ray structure of the human α4β2 nicotinic receptor. Nature
2016, 538, 411–415. [CrossRef] [PubMed]
Azam, L.; McIntosh, J.M. Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to
α-conotoxin RgIA. J. Neurochem. 2012, 122, 1137–1144. [CrossRef] [PubMed]
Christensen, S.B.; Bandyopadhyay, P.K.; Olivera, B.M.; McIntosh, J.M. αS-conotoxin GVIIIB potently and
selectively blocks α9α10 nicotinic acetylcholine receptors. Biochem. Pharmacol. 2015, 96, 349–356. [CrossRef]
[PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

